Loading…
Loading…
LOUISVILLE, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter ended September 30, 2026 after the close of trading on Thursday, November 5. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
New CHEST framework developed by a renowned multidisciplinary panel with expertise in building and managing lung nodule programs across diverse clinical practices New CHEST framework developed by a renowned multidisciplinary panel with expertise in building and managing lung nodule programs across diverse clinical practices
Partnership with Vanderbilt University and Vanderbilt Health accelerates development of the first radiomics-based test for lung nodule risk assessment Partnership with Vanderbilt University and Vanderbilt Health accelerates development of the first radiomics-based test for lung nodule risk assessment
New sponsored and independent research evaluates clinical utility, patient follow-up, and diagnostic test sequencing New sponsored and independent research evaluates clinical utility, patient follow-up, and diagnostic test sequencing
BDSX advances two blood-based MRD programs with Bio-Rad and Thermo Fisher to broaden access to cancer monitoring.
Biodesix-led tumor-informed and tumor-naïve programs draw on the company's bioinformatics and diagnostics test development expertise Biodesix-led tumor-informed and tumor-naïve programs draw on the company's bioinformatics and diagnostics test development expertise
Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules
Biodesix, Inc. (NASDAQ: BDSX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the five analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the